Most Recent
A former Qantas flight attendant who was sacked after getting drunk on peach martinis at a bar while off duty in Manhattan has lost an appeal of a finding that the airline had valid reasons for dismissing him.
The trial in a much anticipated shareholder class action against engineering firm WorleyParsons scheduled to commence this week has hit a roadblock, with a last minute change in the judge that will hear the matter.
An appeals court has overturned a ruling awarding $2 million in compensation to United Petroleum after the state government compulsorily acquired land on which the petrol retailer operated a service station and restaurant.
The ABC paid ousted managing managing director Michelle Guthrie $730,000 to settle a lawsuit alleging unfair dismissal.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
AFT Pharmaceuticals has agreed to a court order temporarily restraining it from distributing point of sale material containing updated claims that its painkiller Maxigesic is more effective than other over-the-counter medications.
Leading defamation barrister Bruce McClintock, SC, has stepped down from representing cricketer Chris Gayle as an appeal by three media organisations against a $326,000 payout gets locked in for a June hearing.
The Australian Building and Construction Commission has been served another costs order after losing a case it brought against a pair of CFMMEU officials who visited a construction site at Melbourne Airport to have a cup of tea with a worker.
Westpac has followed ASIC's lead, launching a separate appeal to a ruling that it provided financial advice but not personal advice as part of a campaign encouraging customers to roll over external superannuation accounts.
German pharmaceutical company Boehringer has struck back at a patent lawsuit brought by Teva, filing a cross-claim alleging Teva is threatening to infringe three of its patents related to its blockbuster inhaler Spiriva with the planned launch of a competing inhaler in Australia.